We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (TriMix-Ipi)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01302496
First Posted: February 24, 2011
Last Update Posted: May 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Vrije Universiteit Brussel
Information provided by (Responsible Party):
Bart Neyns, Universitair Ziekenhuis Brussel
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2017
  Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)